A
Andrey Zaritskey
Researcher at First Pavlov State Medical University of St. Peterburg
Publications - 63
Citations - 2587
Andrey Zaritskey is an academic researcher from First Pavlov State Medical University of St. Peterburg. The author has contributed to research in topics: Population & Nilotinib. The author has an hindex of 15, co-authored 63 publications receiving 1953 citations.
Papers
More filters
Journal ArticleDOI
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus,Michele Baccarani,Richard T. Silver,Charles A. Schiffer,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Michael W. Deininger,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Jeroen Janssen,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Francois-Xavier Mahon,Jiří Mayer,Franck E. Nicolini,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Delphine Rea,Johan Richter,Gianantonio Rosti,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Simona Soverini,Juan Luis Steegmann,Anna G. Turkina,Andrey Zaritskey,Ruediger Hehlmann +33 more
TL;DR: An expert panel to critically evaluate and update the evidence to achieve goals to achieve a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR) in chronic myeloid leukemia.
Journal ArticleDOI
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille N. Abboud,Ellin Berman,Adam D. Cohen,Jorge E. Cortes,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Brian J. Druker,Amir T. Fathi,Elias Jabbour,Madan Jagasia,Hagop M. Kantarjian,Jean Khoury,Pierre Laneuville,Richard A. Larson,Jeffrey H. Lipton,Joseph O. Moore,Tariq I. Mughal,Susan O'Brien,Javier Pinilla-Ibarz,Alfonso Quintás-Cardama,Jerald P. Radich,Vishnu Reddy,Charles A. Schiffer,Neil P. Shah,Paul J. Shami,Richard T. Silver,David S. Snyder,Richard Stone,Moshe Talpaz,Ayalew Tefferi,Richard A. Van Etten,Meir Wetzler,Elisabetta Abruzzese,Jane F. Apperley,Massimo Breccia,Jenny Byrne,Francisco Cervantes,Ekaterina Chelysheva,Richard E. Clark,Hugues de Lavallade,Iryna Dyagil,Carlo Gambacorti-Passerini,John M. Goldman,Ibrahim C. Haznedaroglu,Henrik Hjorth-Hansen,Tessa L. Holyoake,Brian J. P. Huntly,Philipp le Coutre,Elza Lomaia,Francois-Xavier Mahon,David Marin-Costa,Giovanni Martinelli,Jiri Mayer,Dragana Milojkovic,Eduardo Olavarria,Kimmo Porkka,Johan Richter,Philippe Rousselot,Giuseppe Saglio,Güray Saydam,Jesper Stentoft,Anna G. Turkina,Paolo Vigneri,Andrey Zaritskey,Alvaro Aguayo,Manuel Ayala,Israel Bendit,Raquel Bengió,Carlos Best,Eduardo Bullorsky,Eduardo Cervera,Carmino DeSouza,Ernesto Fanilla,David Gómez-Almaguer,Nelson Hamerschlak,José A. López,Alicia Magarinos,Luis Meillon,Jorge Milone,Beatriz Moiraghi,Ricardo Pasquini,Carolina Pavlovsky,Guillermo J. Ruiz-Argüelles,Nelson Spector,Christopher Arthur,Peter Browett,Andrew Grigg,Jianda Hu,Xiao-Jun Huang,Timothy P. Hughes,Qian Jiang,Saengsuree Jootar,Dong-Wook Kim,Hemant Malhotra,Pankaj Malhotra,Itaru Matsumura,Junia V. Melo,Kazunori Ohnishi,Ryuzo Ohno,Tapan Saikia,Anthony P. Schwarer,Naoto Takahashi,Constantine S. Tam,Tetsuzo Tauchi,Kensuke Usuki,Jianxiang Wang,Fawzi Abdel-Rahman,Mahmoud Aljurf,Ali Bazarbachi,Dina Ben Yehuda,Naeem Chaudhri,Muheez A. Durosinmi,Hossam Kamel,Vernon J. Louw,Bassam Francis Matti,Arnon Nagler,Pia Raanani,Ziad Salem +118 more
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Journal ArticleDOI
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury,Jorge E. Cortes,Hagop M. Kantarjian,Carlo Gambacorti-Passerini,Michele Baccarani,Dong-Wook Kim,Andrey Zaritskey,Athena Countouriotis,Nadine Besson,Eric Leip,Virginia Kelly,Tim H. Brümmendorf +11 more
TL;DR: Bosutinib may offer a new treatment option for patients with chronic-phase CML after treatment with multiple TKIs and had an acceptable safety profile; treatment-emergent adverse events were primarily manageable grade 1/2 gastrointestinal events and rash.
Journal ArticleDOI
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
Verena S. Hoffmann,Michele Baccarani,Joerg Hasford,Doris Lindoerfer,Sonja Burgstaller,Dubravka Sertić,Paul Costeas,Jiří Mayer,Karel Indrak,Hele Everaus,Perttu Koskenvesa,Joelle Guilhot,Gabriele Schubert-Fritschle,Fausto Castagnetti,F. Di Raimondo,Sandra Lejniece,Laimonas Griskevicius,Noortje Thielen,Tomasz Sacha,Andrzej Hellmann,Anna G. Turkina,Andrey Zaritskey,Andrija Bogdanovic,Zuzana Sninská,Irena Preloznik Zupan,J-L Steegmann,Bengt Simonsson,Richard E. Clark,A. Covelli,G. Guidi,Ruediger Hehlmann +30 more
TL;DR: The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection, and from a clinical point of view the results of most trials can be generalized to most countries.
Journal ArticleDOI
Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: differences and similarities.
Renata I. Dmitrieva,Izida Minullina,Anna A. Bilibina,Olga V Tarasova,Sergey V. Anisimov,Andrey Zaritskey +5 more
TL;DR: It is demonstrated that specific properties of MSC from different sources should be always taken into account, when developing and optimizing the specific protocols for MSC expansion and evaluation for each particular clinical application.